Amphotericin B for cryptococcal meningitis in HIV positive patients: Low dose versus high dose

Indian Journal of Critical Care Medicine

Volumn 11, Issue 3, 2007, Pages 112-116

  Rajeshwari, S ^a,b   Adhikari, Prabha ^a   Ramapuram, John ^a   Rao, Satish ^a   Pai, M R S M ^a   Kiran, ^a  

^a KASTURBA MEDICAL COLLEGE   (India)

^b KASTURBA MEDICAL COLLEGE   (India)

Author keywords

Amphotericin B; Cryptococal meningitis; Human immunodeficiency virus; Hypokalemia

Indexed keywords

AMPHOTERICIN B; ANTIEMETIC AGENT; ANTIVIRUS AGENT; COTRIMOXAZOLE; DEXAMETHASONE; DICLOFENAC; DOMPERIDONE; ENALAPRIL; INSULIN; MANNITOL; ONDANSETRON; PHENIRAMINE; PYRIMETHAMINE; SULFADOXINE; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; BLOOD ANALYSIS; CEREBROSPINAL FLUID ANALYSIS; CHI SQUARE TEST; CHILL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRYPTOCOCCAL MENINGITIS; DATA ANALYSIS; DIABETES MELLITUS; DRUG DOSE COMPARISON; FACE MALFORMATION; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; KIDNEY DISEASE; MALE; MORTALITY; PNEUMOCYSTIS CARINII; PNEUMONIA; RETROSPECTIVE STUDY; RIGOR; SEIZURE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THROMBOPHLEBITIS; THRUSH; TOXOPLASMOSIS; TUBERCULOSIS; VOMITING;

EID: 35148820581     PISSN: 09725229     EISSN: None     Source Type: Journal    
DOI: 10.4103/0972-5229.35083     Document Type: Article

References (21)

1. Sar B, Monely D, Vann M, Keo C, Sarthou JL, Buisson Y. Increasing invitro resistance in Cryptococcus neoformans Cambodian isolates: April 2000-to 2002. J Antimicrob Chemother 2004;54:563-5.
2. Leenders AC, Reiss P, Portegies P, Clezy K, Hop WC, Hoy J, et al. Liposomal amphotericin B compared with amphotereicin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997;11:1463-71.
3. Philips, Peter. "Fungal infections in AIDS patients". Grand Rounds Infect Dis 1994;4:5-11.
4. Hajjeh RA, Conn LA, Stephens DS, Baughman W, Hamill R, Graviss E, et al. Cryptococcosis: Population-based multi-state active surveillance and risk factors in human immunodeficiency virus infected persons. Cryptococcal Active Surveillance Group. J Infect Dis 1999;179:449-54.
5. Khanna N, Chandramuki A, Desai A, Ravi V, Santosh V, Shankar SK, et al. Cryptococcosis in the immunocompromized host with special reference to AIDS. Indian J Chest Dis Allied Sci 2000;42:311-5.
6. Kumarasamy N, Vallabhaneni S, Flanigan TP, Mayer KH, Solomon S. Clinical profile of HIV in India. Indian J Med Res 2005;121:377-94.
7. rd ed. Saunders: Philadelphia; 1998. p. 582-609.
8. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 to 24 hrs: Randomized controlled trial. BMJ 2001;322:579-82.
9. Pitisuttithum P, Tansuphasawadikal S, Simpson AJ, Howe PA, White NJ. A prospective study of AIDS- associated cryptococcal meningitis in Thailand treatment with high dose amphotericin B. J Infect 2001;43:226-33.
10. van.der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997;337:15-21.
11. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, et al. Comparision of amphotericin B with fluconazole in the treatment of acute ADIS-associated cryptococcal meningitis. N Engl J Med 1992;326:83-9.
12. Walsh TJ, Gonzalez C, Lyman CA, Chanock SJ, Pizzo PA. Invasive fungal infections in children: Recent advances in diagnosis and treatment. Adv Pediatr Infect Dis 1996;11:187-290.
13. Peacock JE, Herrington DA, Cruz JM. Amphotericin B therapy: Past, present and future. Infect Dis Clin Pract 1993;2:81-93.
14. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51.
15. Janknegt R, Marie de S, Bakker Woundenberg IA, Crommelin JA. Liposomal and lipid formulations of amphotericin B: Clinical pharmacokinetics. Clin Pharmacokinet 1992;23:279-91.
16. Graybill JR. Lipid formulations of amphotericin B: Does the emperor need new cloths? Ann Intern Med 1996;124:921-3.
17. Leenders AC, de Marie S. The use of lipid formulations of amphotericin B for systemic fungal infections. Leukemia 1996;10:1570-5.
18. Hsieh SM, Hung CC, Chen MY, Hsueh PR, Chang SC. Efficacy and adverse effects of higher dose amphotericin B monotherapy for cryptococcal meningitis in patients with advanced HIV infection. J Microbiol Immunol Infect 1998;31:233-9.
19. Benett JE. Cryptococosis. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Principles of internal medicine. 16th ed. McGraw Hill: 2005. p. 1183-5.
20. Currie BP, Casadevall A. Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York city. Clin Infect Dis 1994;19:1029-33.
21. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced HIV infection. N Engl J Med 1998;338:853-60.